Trial Profile

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizanlizumab (Primary)
Indications Vaso-occlusive crisis
Focus Registrational; Therapeutic Use
Acronyms STAND
Sponsors Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals

27 Jan 2026 Planned End Date changed from 14 Dec 2026 to 23 Nov 2026.
24 Jan 2024 This trial has been Completed in Greece, According to European Clinical Trials Database record.
12 Dec 2023 Results of pooled analysis from studies (NCT0189536, NCT03264989, NCT03474965 and NCT03814746 )in patients with SCD, presented at 65th Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com